Welcome to our dedicated page for Bridgebio Pharma news (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on Bridgebio Pharma stock.
BridgeBio Pharma, Inc. develops and commercializes medicines for genetic conditions through a decentralized biopharmaceutical model. News for BBIO centers on Attruby/acoramidis, its oral transthyretin stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), including clinical data from ATTRibute-CM, commercial updates, Brazil marketing authorization under the BEYONTTRA name, and licensing or commercialization arrangements.
Company updates also cover late-stage genetic-disease programs such as encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and oral infigratinib for achondroplasia. Recurring financial and corporate items include quarterly results, product revenue trends, capital actions, employee equity inducement grants, investor conference participation, and pipeline regulatory disclosures.
BridgeBio Pharma announced a secondary public offering of 3,000,000 shares of common stock at $62.50 per share, sold by KKR Genetic Disorder L.P. The underwriters have a 30-day option to purchase up to 450,000 additional shares. The offering is set to close on February 17, 2021. The company will not receive any proceeds from the offering as all shares are sold by the stockholder. Goldman Sachs is the book-running manager for the deal. The offering is conducted under an automatic shelf registration statement with the SEC.
BridgeBio Pharma announced a secondary public offering of 3,000,000 shares of its common stock by KKR Genetic Disorder L.P. The underwriters have a 30-day option to purchase an additional 450,000 shares. All shares are sold by the stockholder, with BridgeBio not receiving any proceeds. The offering is part of a previously filed automatic shelf registration statement with the SEC. Goldman Sachs is the book-running manager, supported by KKR Capital Markets and Raymond James. This release does not constitute an offer or solicitation to buy the securities.
BridgeBio Pharma (Nasdaq: BBIO) announced on February 1, 2021, that its compensation committee granted 16,772 restricted stock units to 11 new employees. These awards were made under the 2019 Inducement Equity Plan, adhering to Nasdaq Listing Rule 5635(c)(4). BridgeBio, founded in 2015, focuses on developing transformative medicines for genetic diseases, with over 20 programs in its pipeline targeting Mendelian diseases and genetically driven cancers.
BridgeBio Pharma (BBIO) has completed the acquisition of Eidos Therapeutics, strengthening its clinical and commercial capabilities. This merger, approved by stockholders, focuses on acoramidis, a therapy targeting transthyretin amyloidosis (ATTR), which impacts over 400,000 people globally. BridgeBio anticipates significant data releases for its core programs in 2021 and 2022, with plans to launch two drugs if approved. Eidos shareholders can receive either 1.85 BBIO shares or $73.26 in cash for each Eidos share.
BridgeBio Pharma announced the pricing of $650 million of 2.25% convertible senior notes due 2029, up from a previously planned $400 million. The offering includes an option for initial purchasers to buy an additional $97.5 million in notes, with closing expected on January 28, 2021. These unsecured notes will bear interest at 2.25% annually and have a conversion price of approximately $97.04 per share, representing a 47.5% premium over the January 25 closing price of $65.79. Net proceeds are intended for general corporate purposes, including share repurchases and research funding.
BridgeBio Pharma (Nasdaq: BBIO) announced its plans to offer $400 million in convertible senior notes due 2029, potentially increasing by another $60 million through initial purchasers. The notes will be senior unsecured obligations, bearing interest semi-annually, with specific conversion conditions. Proceeds will fund capped call transactions, share repurchases up to $50 million, and general corporate purposes, including R&D and clinical development. However, the company will not redeem the notes before February 2026, and potential market reactions from related derivative transactions could impact stock prices.
BridgeBio Pharma and Eidos Therapeutics announced that their stockholders approved the acquisition of Eidos by BridgeBio. The merger, expected to close around January 26, 2021, allows Eidos shareholders to choose between receiving 1.85 shares of BridgeBio or $73.26 in cash for each share of Eidos. The cash consideration will be capped at $175 million and prorated if necessary. Both companies aim to leverage Eidos's investigational therapy, acoramidis, targeting transthyretin amyloidosis to enhance value for patients and investors.
BridgeBio Pharma (Nasdaq: BBIO) is set to acquire Eidos Therapeutics (Nasdaq: EIDX) with a transaction expected to close around January 26, 2021. This acquisition is subject to stockholder approvals during special meetings scheduled for January 19, 2021. Eidos shareholders can choose to receive either 1.85 shares of BridgeBio's stock or $73.26 in cash for each Eidos share they own, with the cash portion capped at $175 million. Proxy advisory firms recommend voting in favor of the merger.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on January 4, 2021, the grant of 4,126 restricted stock units to six new employees under its 2019 Inducement Equity Plan, compliant with Nasdaq Listing Rule 5635(c)(4). This plan, adopted in November 2019, aims to provide compensation incentives to attract talent within the biopharmaceutical sector. Founded in 2015, BridgeBio focuses on developing transformative medicines targeting genetic diseases and cancers with genetic drivers, boasting a pipeline of over 20 development programs.
BridgeBio Pharma (NASDAQ: BBIO) has formed a three-year partnership with UC San Francisco (UCSF) to enhance the development of therapies for genetically driven diseases. This collaboration builds on a six-month pilot and aims to expedite the clinical translation of academic innovations into marketable treatments. BridgeBio intends to leverage UCSF's scientific expertise to efficiently bring new medicines to patients. Both organizations express enthusiasm about the partnership, emphasizing the importance of academia-industry collaborations in advancing medical research.